Lymph node metastases: Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience

Marie France Bellin, Catherine Roy, Karen Kinkel, Denis Thoumas, Souhil Zaim, Daniel Vanel, Christine Tuchmann, François Richard, Didier Jacqmin, Annick Delcourt, Emmanuel Challier, Thierry Lebret, Philippe Cluzel

Research output: Contribution to journalArticle

Abstract

PURPOSE: To evaluate the clinical and biological safety of ultrasmall superparamagnetic iron oxide particles (AMI-227) as a contrast agent for magnetic resonance (MR) lymphography and to assess their efficacy for the differentiation of metastatic and benign nodes in patients with urologic and pelvic cancer. MATERIALS AND METHODS: Thirty adults suspected of having lymph node metastases underwent MR imaging before and 22-26 hours after intravenous infusion of AMI-227 (1.7 mg Fe/kg). Sixty histopathologically proved lymph nodes were analyzed on MR images, and 29 of these nodes were also analyzed quantitatively. RESULTS: AMI-227 was well tolerated with no major side effects. It allowed the detection of 10 additional nodes relative to those detected at MR imaging without AMI-227. None of the 27 metastatic nodes showed a decrease in signal intensity (SI) on AMI-227-enhanced images; nine of 27 metastatic nodes showed an increase in SI on T1-weighted images, probably resulting from altered capillary permeability in the tumor. A visually perceptible reduction in SI, indicating active AMI-227 uptake, was observed on postcontrast T2- and T2*-weighted images in 16 of 21 benign nodes. The SI ratio of benign nodes was lower than that of metastatic nodes on T2- and T2*-weighted images. The sensitivity of AMI-227-enhanced MR lymphography was 100%, and the specificity was 80%. CONCLUSION: AMI-227 is safe and may facilitate the differentiation of metastatic and benign nodes in patients with urologic and pelvic cancers.

Original languageEnglish
Pages (from-to)799-808
Number of pages10
JournalRadiology
Volume207
Issue number3
Publication statusPublished - Jun 1998

Fingerprint

Lymph Nodes
Magnetic Resonance Imaging
Neoplasm Metastasis
Safety
Pelvic Neoplasms
Urologic Neoplasms
Lymphography
Magnetic Resonance Spectroscopy
ferumoxtran-10
Capillary Permeability
Intravenous Infusions
Contrast Media
Neoplasms

Keywords

  • Genitourinary system, neoplasms
  • Lymphatic system, MR, 99.12943
  • Lymphatic system, neoplasms, 99.831
  • Magnetic resonance (MR), contrast enhancement, 99.12943
  • Pelvic organs, neoplasms, 80.32

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Bellin, M. F., Roy, C., Kinkel, K., Thoumas, D., Zaim, S., Vanel, D., ... Cluzel, P. (1998). Lymph node metastases: Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience. Radiology, 207(3), 799-808.

Lymph node metastases : Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience. / Bellin, Marie France; Roy, Catherine; Kinkel, Karen; Thoumas, Denis; Zaim, Souhil; Vanel, Daniel; Tuchmann, Christine; Richard, François; Jacqmin, Didier; Delcourt, Annick; Challier, Emmanuel; Lebret, Thierry; Cluzel, Philippe.

In: Radiology, Vol. 207, No. 3, 06.1998, p. 799-808.

Research output: Contribution to journalArticle

Bellin, MF, Roy, C, Kinkel, K, Thoumas, D, Zaim, S, Vanel, D, Tuchmann, C, Richard, F, Jacqmin, D, Delcourt, A, Challier, E, Lebret, T & Cluzel, P 1998, 'Lymph node metastases: Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience', Radiology, vol. 207, no. 3, pp. 799-808.
Bellin, Marie France ; Roy, Catherine ; Kinkel, Karen ; Thoumas, Denis ; Zaim, Souhil ; Vanel, Daniel ; Tuchmann, Christine ; Richard, François ; Jacqmin, Didier ; Delcourt, Annick ; Challier, Emmanuel ; Lebret, Thierry ; Cluzel, Philippe. / Lymph node metastases : Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience. In: Radiology. 1998 ; Vol. 207, No. 3. pp. 799-808.
@article{ca2c7c839728496183c2290149519c4a,
title = "Lymph node metastases: Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience",
abstract = "PURPOSE: To evaluate the clinical and biological safety of ultrasmall superparamagnetic iron oxide particles (AMI-227) as a contrast agent for magnetic resonance (MR) lymphography and to assess their efficacy for the differentiation of metastatic and benign nodes in patients with urologic and pelvic cancer. MATERIALS AND METHODS: Thirty adults suspected of having lymph node metastases underwent MR imaging before and 22-26 hours after intravenous infusion of AMI-227 (1.7 mg Fe/kg). Sixty histopathologically proved lymph nodes were analyzed on MR images, and 29 of these nodes were also analyzed quantitatively. RESULTS: AMI-227 was well tolerated with no major side effects. It allowed the detection of 10 additional nodes relative to those detected at MR imaging without AMI-227. None of the 27 metastatic nodes showed a decrease in signal intensity (SI) on AMI-227-enhanced images; nine of 27 metastatic nodes showed an increase in SI on T1-weighted images, probably resulting from altered capillary permeability in the tumor. A visually perceptible reduction in SI, indicating active AMI-227 uptake, was observed on postcontrast T2- and T2*-weighted images in 16 of 21 benign nodes. The SI ratio of benign nodes was lower than that of metastatic nodes on T2- and T2*-weighted images. The sensitivity of AMI-227-enhanced MR lymphography was 100{\%}, and the specificity was 80{\%}. CONCLUSION: AMI-227 is safe and may facilitate the differentiation of metastatic and benign nodes in patients with urologic and pelvic cancers.",
keywords = "Genitourinary system, neoplasms, Lymphatic system, MR, 99.12943, Lymphatic system, neoplasms, 99.831, Magnetic resonance (MR), contrast enhancement, 99.12943, Pelvic organs, neoplasms, 80.32",
author = "Bellin, {Marie France} and Catherine Roy and Karen Kinkel and Denis Thoumas and Souhil Zaim and Daniel Vanel and Christine Tuchmann and Fran{\cc}ois Richard and Didier Jacqmin and Annick Delcourt and Emmanuel Challier and Thierry Lebret and Philippe Cluzel",
year = "1998",
month = "6",
language = "English",
volume = "207",
pages = "799--808",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "3",

}

TY - JOUR

T1 - Lymph node metastases

T2 - Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience

AU - Bellin, Marie France

AU - Roy, Catherine

AU - Kinkel, Karen

AU - Thoumas, Denis

AU - Zaim, Souhil

AU - Vanel, Daniel

AU - Tuchmann, Christine

AU - Richard, François

AU - Jacqmin, Didier

AU - Delcourt, Annick

AU - Challier, Emmanuel

AU - Lebret, Thierry

AU - Cluzel, Philippe

PY - 1998/6

Y1 - 1998/6

N2 - PURPOSE: To evaluate the clinical and biological safety of ultrasmall superparamagnetic iron oxide particles (AMI-227) as a contrast agent for magnetic resonance (MR) lymphography and to assess their efficacy for the differentiation of metastatic and benign nodes in patients with urologic and pelvic cancer. MATERIALS AND METHODS: Thirty adults suspected of having lymph node metastases underwent MR imaging before and 22-26 hours after intravenous infusion of AMI-227 (1.7 mg Fe/kg). Sixty histopathologically proved lymph nodes were analyzed on MR images, and 29 of these nodes were also analyzed quantitatively. RESULTS: AMI-227 was well tolerated with no major side effects. It allowed the detection of 10 additional nodes relative to those detected at MR imaging without AMI-227. None of the 27 metastatic nodes showed a decrease in signal intensity (SI) on AMI-227-enhanced images; nine of 27 metastatic nodes showed an increase in SI on T1-weighted images, probably resulting from altered capillary permeability in the tumor. A visually perceptible reduction in SI, indicating active AMI-227 uptake, was observed on postcontrast T2- and T2*-weighted images in 16 of 21 benign nodes. The SI ratio of benign nodes was lower than that of metastatic nodes on T2- and T2*-weighted images. The sensitivity of AMI-227-enhanced MR lymphography was 100%, and the specificity was 80%. CONCLUSION: AMI-227 is safe and may facilitate the differentiation of metastatic and benign nodes in patients with urologic and pelvic cancers.

AB - PURPOSE: To evaluate the clinical and biological safety of ultrasmall superparamagnetic iron oxide particles (AMI-227) as a contrast agent for magnetic resonance (MR) lymphography and to assess their efficacy for the differentiation of metastatic and benign nodes in patients with urologic and pelvic cancer. MATERIALS AND METHODS: Thirty adults suspected of having lymph node metastases underwent MR imaging before and 22-26 hours after intravenous infusion of AMI-227 (1.7 mg Fe/kg). Sixty histopathologically proved lymph nodes were analyzed on MR images, and 29 of these nodes were also analyzed quantitatively. RESULTS: AMI-227 was well tolerated with no major side effects. It allowed the detection of 10 additional nodes relative to those detected at MR imaging without AMI-227. None of the 27 metastatic nodes showed a decrease in signal intensity (SI) on AMI-227-enhanced images; nine of 27 metastatic nodes showed an increase in SI on T1-weighted images, probably resulting from altered capillary permeability in the tumor. A visually perceptible reduction in SI, indicating active AMI-227 uptake, was observed on postcontrast T2- and T2*-weighted images in 16 of 21 benign nodes. The SI ratio of benign nodes was lower than that of metastatic nodes on T2- and T2*-weighted images. The sensitivity of AMI-227-enhanced MR lymphography was 100%, and the specificity was 80%. CONCLUSION: AMI-227 is safe and may facilitate the differentiation of metastatic and benign nodes in patients with urologic and pelvic cancers.

KW - Genitourinary system, neoplasms

KW - Lymphatic system, MR, 99.12943

KW - Lymphatic system, neoplasms, 99.831

KW - Magnetic resonance (MR), contrast enhancement, 99.12943

KW - Pelvic organs, neoplasms, 80.32

UR - http://www.scopus.com/inward/record.url?scp=0031841323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031841323&partnerID=8YFLogxK

M3 - Article

C2 - 9609907

AN - SCOPUS:0031841323

VL - 207

SP - 799

EP - 808

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 3

ER -